RxDoctor Payments Data

James Golden

Acute Care · Lubbock, TXNPI 1154659688

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 44 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$357
  • AstraZeneca$166
  • Novartis$142
  • Bayer$103
  • Merck$64
  • Stryker$37
  • plus $184 from 9 others

What the payments were for

  • Food & beverage$99394%
  • Education$606%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,053 in reported general payments places this provider in the 70th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$10,157
Medicare patients
103
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$62,514
EntrestoSacubitril/Valsartan27$20,150
FarxigaDapagliflozin Propanediol33$18,056
JardianceEmpagliflozin19$13,173
BrilintaTicagrelor12$7,449
Metoprolol Succinate137$1,369
Ranolazine ErRanolazine23$1,070
Losartan Potassium96$758
Midodrine Hcl12$710
Rosuvastatin Calcium68$680
Atorvastatin Calcium86$626
Clonidine13$562
Nitroglycerin37$518
Potassium Chloride22$460
Amlodipine Besylate69$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$62,51485 claims
AstraZenecaFarxiga, Brilinta$166$25,50545 claims
NovartisEntresto$142$20,15027 claims
Boehringer IngelheimJardiance$35$13,17319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,323 acute care providers in Texas.

Other acute care in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →